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Available online 30 June 2015AbstractAim: The value of frequent Carcino-Embryonic Antigen (CEA) measurements and CEA-triggered imaging for detecting recurrent disease in
colorectal cancer (CRC) patients was investigated in search for an evidence-based follow-up protocol.
Methods: This is a randomized-controlled multicenter prospective study using a stepped-wedge cluster design. From October 2010 to
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1189C.J. Verberne et al. / EJSO 41 (2015) 1188e1196sequentially changed their usual follow-up care into an intensified follow-up schedule consisting of CEA measurements every two months,
with imaging in case of two CEA rises. The primary outcome measures were the proportion of recurrences that could be treated with cura-
tive intent, recurrences with definitive curative treatment outcome, and the time to detection of recurrent disease.
Results: 3223 patients were included; 243 recurrences were detected (7.5%). A higher proportion of recurrences was detected in the inter-
vention protocol compared to the control protocol (OR ¼ 1.80; 95%-CI: 1.33e2.50; p ¼ 0.0004). The proportion of recurrences that could
be treated with curative intent was higher in the intervention protocol (OR ¼ 2.84; 95%-CI: 1.38e5.86; p ¼ 0.0048) and the proportion of
recurrences with definitive curative treatment outcome was also higher (OR ¼ 3.12, 95%-CI: 1.25e6.02, p-value: 0.0145). The time to
detection of recurrent disease was significantly shorter in the intensified follow-up protocol (HR ¼ 1.45; 95%-CI: 1.08e1.95; p ¼ 0.013).
Conclusion: The CEAwatch protocol detects recurrent disease after colorectal cancer earlier, in a phase that a significantly higher propor-
tion of recurrences can be treated with curative intent.
 2015 Elsevier Ltd. All rights reserved.
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After curative surgical resection of colorectal cancer
(CRC) and termination of adjuvant treatments, patients
are offered a follow-up program consisting of imaging, lab-
oratory measurements, and physical examination to detect
recurrent disease as early as possible. The use of an inten-
sive follow-up regime results in a modest but statistically
relevant improvement in survival compared with a minimal
strategy,1e5 but this conclusion is based on older studies
(inclusion period 1983e2001) and most studies were
considered to be of poor quality.6 The survival gain of
intensive protocols is considered to be the effect of detect-
ing recurrences at an earlier stage, associated with a higher
rate of curative treatment.6,7
Routine imaging with ultrasound of the liver is advised
twice yearly for the first three years and once annually in
years 4 and 5 in the Dutch national guideline (2008)
(www.oncoline.nl). Computed Tomography (CT) scanning
is an alternative with higher sensitivity,8 but it is costly
and has the potential disadvantages of radiation damage9
and false positive findings.10
The tumour marker Carcino-Embryonic Antigen (CEA)
has long been known to be important in signalling recurrent
disease in CRC.11 Intensive follow-up schedules including
CEA measurements are correlated with better survival
than schedules not using CEA measurements,7 and serial
measurements of CEA are recommended in colorectal can-
cer follow-up in all international guidelines.12e14 The rise
and doubling time of CEA rather than the absolute value
are sensitive in signalling recurrent disease.11,15 CEA is
cheap and available, but is irregularly used in follow-up
and has poor protocol adherence.16,17 No studies of serial
CEA measurements and imaging steps in response to sig-
nificant CEA rise, with special attention to reasonable
sensitivity in combination with good specificity, have
been performed so far.
There is a need for an evidence-based follow-up guide-
line defining the optimal frequency and implications of im-
aging and CEA measurements. A phase-2 trial withmonthly CEA measurements showed both high sensitivity
and specificity for detection of recurrences using serial
CEA rises rather than absolute values.18 Therefore, a prom-
ising solution may be frequent CEA testing with imaging
triggered by a significant rise in CEA. The current study
compared a new intensified follow-up schedule with care
as usual in a randomized multicenter trial and aimed to
assess the value of frequent CEA measurements and
CEA-triggered imaging in detecting recurrent disease
with curative possibilities in CRC patients.Materials and methodsTrial designThis was a multicenter stepped-wedge cluster random-
ized (SW-CRT) trial19,20 conducted in 11 non-academic
teaching hospitals in the Netherlands. These hospitals
were randomly grouped into five clusters. Detailed explana-
tion on the motivation of using this trial design is given by
Zhan et al.21
In an SW-CRT, all clusters cross over from control to
intervention at certain time points called switches. Instead
of randomizing patients to treatment arms, randomization
is used to allocate clusters to predefined switches. For the
CEAwatch trial, each of the clusters was randomly
switched to change from the usual follow-up schedule (con-
trol) to the intensive follow-up schedule (intervention);
crossover occurred in one direction only. From October
2010 clusters switched from usual follow-up to intensive
follow-up every three months one by one; the length be-
tween two consecutive switches was three months (Fig. 1).
Randomization was performed independently by Trial
Coordination Center (TCC) Groningen (www.tcc.umcg.
nl). CEAwatch (Netherlands Trial Register [NTR] 2182)
was approved by the Medical Ethics Committee of the Uni-
versity Medical Centre Groningen (METc-UMCG
2010.064) and the local ethics committees of all partici-
pating centres. CEAwatch was sponsored by the
Netherlands Organization for Health Research and
Figure 1. Graphic depiction of the stepped wedge cluster randomized trial.
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ples of Good Clinical Practice.ParticipantsEligible patients were patients with AJCC stage IeIII
CRC after R0 resection. Patients operated on from 2007
to July 2012 were included. At October 2010, patients
who were already in follow-up in the participating hospitals
since 2007 were included. Between October 2010 and
October 2012, all new patients that entered follow-up in
the participating hospitals were included and assigned to
the actual protocol of that hospital.
Patients who were not medically fit for metastasectomy,
patients diagnosed with other malignancies and patients
with metachronous metastases at the start of the study
were excluded.Patient identification and validationEligible patients were identified using the diagnosis or
operation code(s). At the end of patient recruitment
(October 2012), eligibility of all patients was validated us-
ing the database of the Dutch Comprehensive Cancer Cen-
ter (NCCC), a registry of all diagnosed malignancies based
on the automated pathological archive (www.iknl.nl).
Patients’ characteristics were obtained directly from the
Dutch Surgical Colorectal Audit (DSCA) and stored in a
password-protected database. DSCA is a national databank
gathering all relevant information on surgically treated
CRC patients, allowing a valid and complete registration
of all CRC patients in the Netherlands (www.
clinicalaudit.nl/dsca).Follow-up schedulesThe control or “care-as-usual” protocol consisted of the
national guideline in the Netherlands in 2008 (www.
oncoline.nl); an outpatient clinic visit every six months
for the first three years and an annual visit in years 4 and
5. Liver ultrasound and chest X-ray were recommended
at each clinic visit. CEA (half-life: 5 days) was measuredevery 3e6 months in the first three years and each year
in the last two years.
The intervention follow-up protocol adhered to bi-
monthly CEA measurements and yearly imaging in the first
three years, and 3-monthly CEA measurements in the
fourth and fifth years of follow-up. Outpatient clinic visits
with imaging of chest and abdomen were performed annu-
ally in the first three years. In case of an increase of 20%
compared with the previous CEA with CEA value
>2.5 ng/mL, another blood sample was drawn four weeks
later. If a consecutive rise were was observed, a CT scan
of chest and abdomen was advised (Fig. 2). The static
normal value of serum-CEA as advised by manufacturers
is 2.0e2.5 ng/mL, depending on the actual test.
The coordination and monitoring of this process was
supported by an automatic computer system.22ImplementationPatients entering the study before the switch were fol-
lowed using the control protocol and switched to the inter-
vention after their hospital’s switch. Patients entering the
study after the randomized switch of a hospital were fol-
lowed using the intervention protocol only. Patients who
met the inclusion criteria on October 1st, 2010, but no
longer met these criteria at the switch date participated in
the control protocol only. Informed consent was obtained
before entering the intervention for all patients as required
by the Medical Ethical Committee.OutcomesThe primary outcome measures were the number of re-
currences per follow-up arm, the proportion of recurrences
that could be treated with curative intent, the proportion of
recurrences with definitive curative treatment outcome (R0
resection of all recurrent disease), and the time to detection
of recurrent disease.Power calculationThe expected percentage of resectable recurrences was
10% in the control protocol and 25% in the intensified pro-
tocol.23,24 Given a significance level of 5% and a power of
80%, 115 patients with recurrent disease in both groups
were needed. Given an expected recurrence rate of
25%,25 460 patients per group were needed. Given the clus-
ter randomization, we assumed a correlation of 0.1 between
hospitals, yielding a correction factor of 1.71.26 Therefore,
a minimum of about 800 patients per group was needed.Data analysisDifferences in patients’ baseline characteristics between
the care as usual follow-up and the intensified follow-up
Figure 2. Follow-up schedules.
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tests.
For each of the three outcomes (recurrence, recurrence
with curative intent and recurrence with definite curative
treatment outcome), pooled logistic regression was per-
formed to compare the proportion of each outcome between
the control follow-up protocol and the intensified follow-up
due to the fact that standard statistical technique cannot
address the dynamic settings of the follow-up protocol.
The study duration was divided into six intervals by the
five switch moments. The conditional probability of the
outcome measures in each interval, given that this did not
happen prior to this interval, was modelled as the dependent
variable and the follow-up protocol of each interval was
modelled as the independent variable. Meanwhile general-
ized estimation equation (GEE) was used to allow flexible
assumptions of the correlations between each interval.
Odds Ratios (OR) with 95% confidence intervals (95%-
CIs) were reported for the effects of the intensified
follow-up protocols on the detection of recurrences, detec-
tion of recurrences treated with curative intent and recur-
rences with definitive treatment outcome. The Cox
proportional hazard model was used to investigate the dif-
ferences in time till detection of recurrent disease between
the follow-up protocols. The follow-up protocols were used
as a time-dependent variable since the time in follow-up
was dynamic. The time from operation to participation in
the study created left truncated data for a subset of patients.
Stratification for hospitals was applied. The intervention ef-
fect was corrected for gender, age, AJCC stage, andlocation of the primary tumour and it was reported as haz-
ard ratios (HR) with 95%-CIs. Statistical modelling was
performed with SAS statistical software, version 9.3.
ResultsInclusionsFrom 1-1-2007 till 01-10-2010, 5604 patients from 11
hospitals with stage AJCC IeIII colorectal cancer were
registered by the Netherlands Cancer Registration; 118 pa-
tients were not identified in the hospitals. Of these patients,
2318 met the inclusion criteria; their follow-up data were
prospectively collected from 01-10-2010. During the con-
trol period, there were 589 eligible new patients identified
before the switch dates; 116 patients reached an endpoint
(not fit for metastasectomy, recurrent disease before switch
date, or other) during the control period. A total of 2791 pa-
tients were asked for informed consent prior to the switch
dates. Of these, 1725 patients provided written informed
consent. For the remaining 1066 patients, prospective
data collection of follow-up data ended on the switch dates.
During the intervention period, an additional 316 patients
gave written informed consent to participate in the intensive
follow-up protocol.
A total of 3223 patients were included. 1725 patients
participated both in the control protocol and in the interven-
tion protocol, 1182 patients participated only in the control
protocol, and 316 patients participated only in the interven-
tion protocol (Fig. 3).
Figure 3. Inclusions.
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the intervention period comprised 2041 patients. Patient’s
characteristics are given in Table 1. The differences be-
tween eligible patients who decided to participate and
eligible patients who decided not to participate in the inter-
vention protocol are shown in Table 2.RecurrencesA total of 243 (7.5%) recurrences were detected during
the study (Table 3). 104 (43%) recurrences were found
while the patient participated in the control protocol and
139 (57%) recurrences were detected while the patient
participated in the intervention protocol. 90 (37.0%) of all
recurrences could be treated with curative intent.
The proportion of detected recurrences eligible for
curative treatment during the intervention protocol was
higher than in the control protocol (42.0% versus
30.0%). Further analysis with results of real pathology
(treatment outcome instead of treatment intent) showed
that and 70 (78%) of all detected recurrences treated
with curative intent had definite curative treatment
outcome based on pathology: the proportion of curativetreatment outcome was also higher in the intervention
than in the control (35% versus 22%).
The location of detected recurrences (p ¼ 0.134), AJCC
stage of the primary tumour (p ¼ 0.978) and the location of
the primary tumour (p ¼ 0.261) were not different in both
follow-up protocols.
Pooled logistic regression showed statistically signifi-
cant higher proportion of recurrences in the intervention
protocol compared to the control protocol (OR ¼ 1.80,
95%-CI: 1.33e2.50, p-value: 0.0004). The proportion of re-
currences that could be treated with curative intent was also
statistically significant higher in the intervention protocol
(OR ¼ 2.84, 95%-CI: 1.38e5.86, p-value: 0.0048).
The OR of recurrences with definite curative treatment
outcome was also higher in the intervention protocol
(OR ¼ 3.12, 95%-CI: 1.25e6.02, p-value: 0.0145).
The time to diagnosis of recurrent disease, corrected for
age, gender, AJCC stage and location of the primary
tumour, and stratified by hospital using the Cox propor-
tional hazard model, decreased with the intervention
follow-up protocol as compared to the control protocol
(HR: 1.45; 95%-CI: 1.08e1.95; p ¼ 0.013). This was
also shown for the recurrences treated with curative intent
Table 1
Patient’s and tumour characteristics (N (%)).
Characteristic Patients only in
control period
Patients in control
and intervention period
Patients only in
intervention period
Total p-valuea
Total (%) 1182 (37) 1725 (53) 316 (10) 3223 (100)
Gender <0.01
Male 603 (51) 1024 (59) 180 (57) 1807 (56)
Female 579 (49) 701 (41) 136 (43) 1416 (44)
Age at diagnosis (years) <0.01
Median (range) 73 (26e95) 69 (30e93) 67 (29e92) 70 (26e95)
AJCC stageb <0.01
I 281 (24) 504 (29) 92 (29) 877 (28)
II 462 (39) 670 (39) 137 (43) 1269 (39)
III 439 (37) 551 (32) 87 (28) 1077 (33)
Location primary tumour 0.4
Colon 754 (64) 1068 (62) 206 (65) 2028 (63)
Rectum 428 (36) 657 (38) 110 (35) 1195 (37)
Adjuvant chemotherapyc 299 (43) 337 (49) 55 (8) 691 (100) 0.04
Yes 187 (63) 249 (74) 45 (82) 481 (70)
No 112 (37) 88 (26) 10 (18) 210 (30)
Patients with comorbidityd 370 (31) 768 (56) 225 (17) 1363 (100) 0.06
None 145 (39) 369 (48) 95 (42) 609 (45)
Minor 195 (53) 341 (44) 114 (51) 650 (48)
Major 30 (8) 58 (8) 16 (7) 104 (7)
a These p-values were calculated using ANOVA and Chi-Square tests.
b AJCC: American Joint Committee on Cancer.
c For adjuvant chemotherapy, only patients with stage III colon cancers are shown.
d For comorbidity, only patients with known comorbidity are shown. P-value is calculated for the group with no comorbidity versus minor or major
comorbidity.
Table 2
Comparison between patients deciding to participate in the intervention follow-up protocol and patients deciding not to participate in the intervention
protocol.
Characteristic All patients eligible
for intervention protocol
Patients not crossing over to
intervention protocola
Patients crossing over to
intervention protocol
p-valueb
Total 2791 (100) 1066 (38.2) 1725 (61.8) NA
Gender NA
Male 1562 (56) 538 (50) 1024 (59)
Female 1229 (44) 528 (50) 701 (41)
Age at diagnosis (years) 0.001
Median (range) 70 (26e95) 73 (26e95) 69 (30e93)
AJCC stage primary tumourc 0.44
I 767 (27) 263 (25) 504 (29)
II 1093 (39) 423 (40) 670 (39)
III 931 (34) 380 (35) 551 (32)
Location primary tumour 0.45
Colon 1744 (63) 676 (63) 1068 (62)
Rectum 1047 (37) 390 (37) 657 (38)
Adjuvant chemotherapy 0.13
Yes 737 (26) 295 (28) 442 (6)
No 2054 (73) 771 (72) 1283 (74)
Patients with comorbidityd 1121 (100) 353 (32) 768 (68) 0.01
None 509 (45) 140 (40) 369 (48)
Minor 528 (47) 187 (53) 341 (44)
Major 84 (8) 26 (7) 58 (8)
a These were all the patients eligible to cross over who did not consent to cross-over to the new follow-up regimen.
b These p-values were calculated using ANOVA and Chi-Square tests.
c AJCC: American Joint Committee on Cancer.
d For comorbidity, only patients with known comorbidity are shown. p-value is calculated for the group with no comorbidity versus minor or major
comorbidity.
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Table 3
Location and treatment of recurrences in control and intervention protocol
(N; %).
Variable Total Control
period
Intervention
period
p-valuea
Recurrent disease 243 (8) 104 (43) 139 (57) <0.001
Treatment for
recurrent disease
0.03
Curative 90 (37) 31 (30) 59 (42)
Palliative 153 (63) 74 (70) 79 (58)
Location of
recurrent disease
0.13b
Liver 89 (36) 41 (39) 48 (35)
Local recurrence 44 (18) 13 (13) 31 (22)
Lymph nodes 15 (6) 8 (8) 7 (5)
Lung 48 (20) 17 (16) 31 (22)
Other 24 (10) 15 (14) 9 (7)
Combination 23 (10) 10 (10) 13 (9)
AJCC stage primary
tumour
0.98c
I 23 (9.5) 10 (9.6) 13 (9)
II 89 (36.6) 36 (34.6) 53 (38)
III 131 (53.9) 58 (55.8) 73 (53)
Location primary tumour 0.26
Colon 145 (60) 68 (65) 77 (55)
Rectum 98 (40) 36 (35) 62 (45)
a These p-values were calculated with a logistic regression stratified for
centre.
b This p-value was calculated by comparing recurrences in liver versus in
other locations, stratified for centre.
c This p-value was calculated by comparing AJCC stage I and II versus
III, stratified for centre.
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with definite curative treatment outcome (HR: 6.27; 95%-
CI: 3.82e10.30; p < 0.0001).
Discussion
In the current study including 3223 patients, it is shown
that an intensified follow-up schedule with frequent CEA
measurements, CEA slope analyses instead of absolute
values and imaging in case of two subsequent CEA rises
detects recurrences with higher rate of curable options
(42% versus 30%), higher rate of definitive treatment
outcome (35% versus 22%) and less time-to-detection
compared to a care as usual follow-up protocol. To date
there has been no randomized trial for colorectal cancer
follow-up with so many participants.
Intensity of colorectal cancer follow-up schedules has
been the subject of discussion for decades but in the studies
performed to date both the use of CEA and imaging are het-
erogeneous between studies.1,2,4,5,8,27 All performed studies
so far lack a description of a systematic plan of action in
case of a CEA rise resulting in the impossibility to describe
the best combination of techniques for the ideal CRC
follow-up.7 The expanding options for curing liver metasta-
ses show that intensive systematic searching for liver me-
tastases is worthwhile.28,29 At least as important is the
growing evidence that limited extrahepatic diseases aswell as local recurrent disease are no longer an absolute
contraindication for intended curative treatment.30,31 How-
ever, the definition of curable or resectable recurrences is
difficult and differs per hospital, especially for Radio-
Frequent Ablation options and stereotactic radiation
therapy.32
An optimal follow-up schedule should detect recur-
rences in an early stage. The balance between false positive
findings as a result of a too sensitive test reflecting normal
CEA variations or not yet detectable recurrent disease and
the too late detection is crucial. An analysis on older data
using CEA showed a lack of survival improvement for
second-look operations based on CEA rise.33 The FACS
trial, a randomized trial comparing minimal and intensive
follow-up, recently confirmed that regular CEA measure-
ments, CT scanning and CEA with CT scanning result in
significantly higher rates of curable recurrences compared
to minimum follow-up (resp 7.6%, 9.5%, 7.3% and
1.5).34 However there was no survival improvement be-
tween the different follow-up protocols in this study. A
recent systematic review and meta-analysis included next
to the FACS trial all old studies; a modest survival improve-
ment for intensified protocols was shown.6 However, it can
be questioned whether this estimate is unbiased since the
incidence of recurrences is lowering and the options for
cure of recurrences are expanding, and only one recent
study was included in the meta-analysis. Data from two
other prospective trials (the COLOFOL trial35 and the
GILDA trial,36 both comparing overall and disease-
specific survival between different follow-up schedules)
will become available.
Relatively few recurrences (7.5%) were found in the
here presented study; the expected recurrence rate for
AJCC stages IeIII of colorectal carcinomas is about
20%.37 In the FACS study this percentage is also lower in
comparison with the older literature, namely 16%. The
Dutch national guideline on routine preoperative staging
with CT scan seems to result in more synchronous and
less metachronous metastases.38 Hereby the intention of
the study is to cover a period of five years of follow-up
and patients with a disease-free period before the schedule
started were included. The prospective data collection of
these patients started sometimes 2e3 year after resection,
decreasing the expected recurrence rate. The total number
of patients included was high enough to detect statistically
significant differences.
A strong point in this study is the high data integrity, as
all data on patients’ and tumour characteristics were ex-
ported from a national audit which is known to be filled
out for up to 97% of all colorectal cancer patients (www.
clinicalaudit.nl). Data monitoring was performed through
a secondary validation using the NCCC, which is the com-
plete cancer registration in the Netherlands. Another strong
point of this study was the uniformity of the intervention
protocol and high adherence to the protocol. This was the
result of a software-support system for the management
1195C.J. Verberne et al. / EJSO 41 (2015) 1188e1196of all patients in the intervention group, an intranet-based
software system written to support clinicians working
with patients in follow-up. The software support has been
shown to be safe and efficient.22
Internationally, CT scanning is common practice and ul-
trasound with thoracic X-ray which seem a bit old-
fashioned. However this study is performed to compare
the usual follow-up with a new schedule; the study was per-
formed during the time that the 2008 Dutch national guide-
line was used and this guideline advised X-ray and
ultrasound.
The SW-CRT has not previously been used for the pur-
poses of a follow-up study. Advantages of the design are
the inclusion of large patient groups in a short time period
and the avoiding of in-hospital protocol contamination. On
the other hand, patients participating in both follow-up pro-
tocols are always later in the intervention protocol than in
the control protocol, which makes the SW-CRT not a
pure RCT. Meanwhile, the incidence of recurrence tends
to change over time during follow-up. Most recurrences
are found in the first two years of follow-up, but retaining
percentages of recurrences are seen in the years there-
after.29 Thus, it can never be known whether the observed
effects are completely due to the intervention. However,
as shown in the results, the increase in resectable recur-
rences was not entirely due to the increases of recurrences
since the effect size of the intervention is much larger for
resectable recurrences.
The current study shows that an intensified protocol with
CEA and assessment on CEA rise rather than absolute
value detects recurrences earlier than the standard protocol,
which is related to an increase in curable recurrence rate.
The results advocate an intensification of CEA measure-
ments and more frequent action at CEA rises in follow-
up. The FACS study is using an absolute CEA cut-off point
of 7 mg/l compared to baseline instead of slope analyses; in
the discussion the authors advocate further analyses on this
matter, but in the current results of this study, already ad-
dressing CEA changes, no further conclusions on this topic
can be drawn. The final proof of the value and strength of
this new protocol will be if the effects of the intensified
CEA-based follow-up strategy will result in higher
disease-specific and overall survival, with acceptable qual-
ity of life and cost-effectiveness rates.
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